Natixis’s Procept Biorobotics PRCT Stock Holding History

Natixis’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.9K	Buy	+3,935	New	+$98.5K	﹤0.01%	1000
2025 Q2	–	Sell	-40,900	Closed	-$2.33M	–	1140
2025 Q1	$2.33M	Buy	+40,900	New	+$2.79M	0.01%	404
2024 Q1	–	Sell	-31,310	Closed	-$1.31M	–	1178
2023 Q4	$1.31M	Buy	31,310 +30,666	+4,762%	+$1.04M	0.01%	476
2023 Q3	$21.1K	Sell	644 -44,258	-99%	-$1.51M	﹤0.01%	869
2023 Q2	$1.56M	Sell	44,902 -254	-0.6%	-$8.4K	0.01%	468
2023 Q1	$1.25M	Sell	45,156 -47,848	-51%	-$1.69M	0.01%	489
2022 Q4	$3.86M	Buy	93,004 +44,832	+93%	+$1.93M	0.02%	424
2022 Q3	$2.03M	Buy	48,172 +22,114	+85%	+$882K	0.01%	607
2022 Q2	$862K	Buy	+26,058	New	+$948K	﹤0.01%	852

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Natixis's PRCT Position: Q2 2026 in Review

Natixis opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 3,935 shares worth $88.9K. The stake represents ﹤0.01% of the portfolio and ranks #1000 among its holdings. This is a return to the name: Natixis previously reported a position in PRCT as recently as Q1 2025.

Natixis first reported a position in PRCT in Q2 2022 and has held it in 9 quarters since. The position peaked at $3.86M in Q4 2022. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Natixis held 3,935 shares of Procept Biorobotics worth $88.9K as of Q2 2026.
Procept Biorobotics was a new Natixis position in Q2 2026.
Procept Biorobotics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1000 holding.
Natixis first reported a position in Procept Biorobotics in Q2 2022 and has held it in 9 quarters since.
Natixis's Procept Biorobotics position peaked at $3.86M in Q4 2022.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.